FACE: the barefaced facts of AI potency.

12 As with the monotherapy analysis, despite the crossover of patients from tamoxifen to letrozole, there was a significant benefit of letrozole over tamoxifen in DFS (585 vs 664 events, Table 1 ), TTR (368 vs 441 events, HR 0.82; 95% CI: 0.71–0.94; P = 0.004), and TTDR (287 vs 357 events, Table 1 ), and a strong trend in OS favoring letrozole (330 vs 374 events, Table 1 ).

also in 5,725 other papers

Importantly, there was a pronounced trend in favor of letrozole in OS compared with tamoxifen.

also in 237 other papers